检索结果-内蒙古大学图书馆

浙江大学学报（医学版） 2017年第4期46卷 397-404页

作者：冯学问陈智才钟根龙楼敏浙江大学医学院附属第二医院神经内科浙江杭州310009 温岭市第一人民医院神经内科浙江温岭317500

目的:探讨急性缺血性卒中患者血管内治疗后使用替罗非班的安全性及预后分析。方法:回顾性分析2013年10月至2017年4月在浙江大学医学院附属第二医院接受静脉溶栓桥接动脉取栓或直接动脉取栓的急性缺血性卒中患者115例的临床资料。根据患... 详细信息

目的:探讨急性缺血性卒中患者血管内治疗后使用替罗非班的安全性及预后分析。方法:回顾性分析2013年10月至2017年4月在浙江大学医学院附属第二医院接受静脉溶栓桥接动脉取栓或直接动脉取栓的急性缺血性卒中患者115例的临床资料。根据患者术后24 h内是否使用替罗非班治疗分为替罗非班组(30例)和对照组(85例)。参照欧洲协作性急性卒中研究(ECASS)Ⅱ标准评估24 h内的出血转化,治疗后3个月时改良Rankin量表(mRS)超过2分定义为预后不优。采用二元logistic回归分析治疗后使用替罗非班是否独立影响患者出血转化和3个月临床预后。结果:二元logistic回归分析提示,替罗非班治疗不增加出血转化的风险(OR=0.437,95%CI:0.168~1.132,P>0.05);患者基线美国国立卫生研究院卒中量表(NIHSS)评分(OR=1.136,95%CI:1.014~1.273,P<0.05)、血管再通(OR=0.060,95%CI:0.010~0.365,P<0.01)、高血压(OR=4.233,95%CI:1.320~13.570,P<0.05)和起病至治疗时间(OR=1 006,95%CI:1.001~1.011,P<0.05)与临床预后不优独立相关,而替罗非班治疗与临床预后不优无独立相关性(OR=1.923,95%CI:0.536~6.568,P>0.05)。结论:急性缺血性卒中患者血管内治疗后使用替罗非班不会增加出血转化的风险。

关键词：动脉闭塞性疾病/药物疗法脑缺血/治疗血栓溶解疗法酪氨霞龟/ 类似物和衍生物血小板膜糖蛋白类/拮抗剂和抑制剂出血/预防和控制预后

来源：评论

学校读者我要写书评

暂无评论

动态CT血管造影评估急性基底动脉闭塞患者侧支血流与再灌注治疗预后的关系

引用

浙江大学学报（医学版） 2017年第4期46卷 371-376页

作者：赖针珍张圣钟根龙张晓程陈清梦楼敏浙江大学医学院附属第二医院神经内科浙江杭州310009 浙江省天台县人民医院神经内科浙江天台317200

目的:研究动态CT血管造影对急性基底动脉闭塞所致缺血性卒中患者侧支血流状态评估以及预测再灌注治疗后结局的价值。方法:回顾性分析2012年1月至2016年8月在浙江大学医学院附属第二医院接受再灌注治疗的45例急性基底动脉闭塞所致缺血性... 详细信息

目的:研究动态CT血管造影对急性基底动脉闭塞所致缺血性卒中患者侧支血流状态评估以及预测再灌注治疗后结局的价值。方法:回顾性分析2012年1月至2016年8月在浙江大学医学院附属第二医院接受再灌注治疗的45例急性基底动脉闭塞所致缺血性卒中患者的临床资料。采用单因素和二元logistic回归模型分析患者预后的独立预测因素,并采用受试者工作特征(ROC)曲线确定预测患者预后的后循环侧支评分(PC-CS)的最佳阈值。结果:二元logistic回归分析提示,基线美国国立卫生研究院卒中量表(NIHSS)评分(OR=0.886,95%CI:0.802~0.979,P<0.05)和PC-CS(OR=1.962,95%CI:1.026~3.752,P<0.05)是患者预后的独立预测因素,且PC-CS4.5分是预测患者预后的最佳阈值(AUC=0.837,敏感度为68.2%,特异度为87.0%)。结论:基于CT灌注成像重建的动态CT血管造影可用于评估后循环侧支血流状态,并能预测急性基底动脉闭塞所致缺血性卒中患者再灌注治疗后的临床结局。

关键词：基底动脉侧支循环再灌注动脉闭塞性疾病/药物疗法卒中/药物疗法血流动力学血管造影术数字减影体层摄影术 X线计算机/方法血栓溶解疗法/方法预后

来源：评论

学校读者我要写书评

暂无评论

THROMBOLYTIC TREATMENT WITH IV BRINASE OF ADVANCED ARTERIAL OBLITERATIVE DISEASE OF LIMBS

引用

ANGIOLOGY 1975年第7期26卷 534-556页

作者： LUND, F EKESTROM, S FRISCH, EP MAGAARD, F STUREBY SJUKHUS GERIATRIC UNIT ENSKEDESWEDEN KAROLINSKA SJUKHUSET THORAC SURG CLINSTOCKHOLMSWEDEN AB ASTRA MED DEPT SODERTALJESWEDEN

The material includes 17 patients suffering from different degrees of chronic peripheral arterial disease (11 chronic patients stage III and IV, two patients with acute arterial occlusion, and four patients stage II). Presence and extent of arterial occlusion was ascertained by initial arteriography. In twelve of the patients amputation had been considered. The patients were treated by a series of i.v. infusions of brinase, a proteolytic enzyme from Aspergillus oryzae. The brinase inhibitor capacity in plasma was determined by the azocollagen technique. Dosage of brinase was calculated to retain a rest inhibitor capacity in order to avoid free proteolytic activity. In five patients the enzyme was also given preoperatively by intra arterial instillation prior to a series of i.v. brinase infusions. Thirteen patients showed clinical improvement after brinase treatment. The condition of two patients remained unchanged, and in two patients amputation could not be avoided. In fourteen patients the treatment results were followed by measurement of peripheral systolic blood pressure. In ten patients obvious increase of the peripheral systolic blood pressure was observed. Cutaneous microcirculation was studied in seven patients by i.v. sequential fluorescein angiography and signs of improved microcirculation (appearance time, intensity and/or extent of fluorescence) were found in all examined patients. One patient with acute arterial occlusion of the right leg with obstruction of blood flow from the external iliac artery showed complete disobliteration after a series of i.v. brinase infusions. Bleeding complications associated with brinase treatment were not observed in the material. In three patients brinase treatment was discontinued because of complications (2 brinase, 1 heparin).

关键词：动脉闭塞性疾病/药物疗法动脉闭塞性疾病/病理生理学米曲霉溶纤维蛋白酶/治疗应用荧光素血管造影术输注静脉内肽水解酶类/治疗应用局部血流皮肤温度成年人老年人女(雌)性人类男(雄)性中年人

来源：评论

学校读者我要写书评

暂无评论

Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT)

引用

AMERICAN HEART JOURNAL 2000年第4期140卷 631-636页

作者： Chesney, CM Elam, MB Herd, JA Davis, KB Garg, R Hunninghake, D Kennedy, JW Applegate, WB Baptist Mem Hosp Dept Pathol Memphis TN 38146 USA Univ Tennessee Dept Med Memphis TN 38104 USA Univ Tennessee Dept Pathol Memphis TN 38104 USA Memphis Vet Affairs Med Ctr Memphis TN USA Univ Tennessee Div Clin Pharmacol Dept Pharmacol Memphis TN 38163 USA Univ Tennessee Dept Prevent Med Memphis TN 38163 USA Baylor Univ Houston TX 77030 USA Univ Washington Seattle WA 98195 USA Eli Lilly & Co Indianapolis IN 46285 USA Univ Minnesota Sch Med Heart Dis Prevent Clin Minneapolis MN 55455 USA Univ Minnesota Sch Med Vasc Med Program Minneapolis MN 55455 USA

Background Patients with peripheral arterial disease (PAD) have high rates of cardiovascular morbidity and mortality, including that caused by associated coronary heart disease and cerebrovascular disease. Previous studies have shown that coagulation parameters are altered in PAD and that altered coagulation may play a critical role in the susceptibility to cardiovascular complications in PAD. It is therefore important to assess the effect of secondary prevention measures on coagulation in patients with PAD. The Arterial Disease Multiple intervention Trial (ADMIT), a multicenter, randomized, placebo-controlled trial, was conducted to determine the feasibility of a combined lipid-modifying, antioxidant, and antithrombotic treatment regimen in patients with PAD. The objective of this study was to assess the effect of the ADMIT interventions on coagulation. Methods ADMIT participants were randomly assigned to low-dose warfarin, niacin, and antioxidant vitamin cocktail or corresponding placebos in a 2 x 2 x 2 factorial design. Specialized coagulation studies were performed in a subset of 80 ADMIT participants at baseline and after 12 months of treatment. Results Low-dose warfarin (1 to 4 mg/d) resulted in a significant decrease in factor Vile (P< .001) and in plasma F1.2 (P = .001). Unexpectedly, niacin treatment also resulted in significant decrease in both fibrinogen (48 mg/dl;P< .001) and F1.2 (P= .04). von Willebrand factor increased after antioxidant vitamin treatment (P= .04). Conclusions A regimen of low-dose warfarin effectively modifies coagulation in patients with PAD. Niacin also favorably modifies Fibrinogen and plasma F1.2. Niacin, in addition to its lipid effects, modifies abnormal coagulation factors that accompany PAD.

关键词：抗凝药/治疗应用抗氧化剂/治疗应用动脉闭塞性疾病/血液动脉闭塞性疾病/药物疗法抗坏血酸/治疗应用血液凝固/药物作用疾病恶化药物疗法联合可行性研究纤维蛋白原/代谢尼克酸/治疗应用维生素E/治疗应用华法林/治疗应用 β胡萝卜素/治疗应用 vonWillebrand因子/代谢老年人女(雌)性人类男(雄)性

来源：评论

学校读者我要写书评

暂无评论

Intravenous prostaglandin E₁ reduces soluble vascular cell adhesion molecule-1 in peripheral arterial obstructive disease

引用

AMERICAN HEART JOURNAL 2001年第4期142卷 733-739页

作者： Gianetti, J De Caterina, M de Cristofaro, T Ungaro, B Biol, D Del Guercio, R De Caterina, R CNR Inst Clin Physiol Lab Thrombosis & Vasc Res I-56100 Pisa Italy Univ G dAnnunzio Dept Cardiol Chieti Italy Univ Naples 2 Dept Internal Med Naples Italy Univ Naples Federico II Dept Biochem Naples Italy Univ Naples Federico II Dept Med Biotechnol Naples Italy

Objectives Elevated levels of soluble (s) vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1, pointing to activation of cells involved in vascular inflammation, have been previously reported in peripheral arterial obstructive disease (PAOD). We tested the hypothesis that intravenous prostaglandin E-1 (PGE(1)) treatment, which produces clinical benefits in this condition, might decrease such levels. Methods Ten subjects (age range 58 +/- 10 years, 6 male, 4 female) with characterized Fontaine stage IIa to IV PAOD (ankle/arm pressure index <0.96) were entered into a treatment protocol with twice daily intravenous infusions of PGE(1) (alprostadil) at 120 mug per day, repeated for 10 consecutive days. Preinfusion and postinfusion plasma samples were stored for blind enzyme immunoassays of soluble adhesion molecules and the fibrinolytic marker tissue plasminogen activator, type-1 plasminogen-activator inhibitor, and D-dimer. Results Estimates of severity of pain at rest, consumption of analgesics, magnitude of trophic lesions, remission to lower Fontaine stages, and favorable changes in the venoarteriolar reflex documented significant beneficial effects of the treatment. Significant (P < .01) pretreatment and posttreatment reductions of in all soluble markers explored were found. Particularly, sVCAM-1 exhibited a significant decrease after each infusion, which was sustained at the last day of treatment (from 854 +/- 214 ng/mL to 775 +/- 215 ng/mL across the first infusion, from 773 +/- 146 ng/mL to 680 +/- 110 ng/mL across the last infusion). Conclusion Thus a global decrease of vascular cell activation appears to occur as a result of PGE, administration and may contribute to the observed clinical benefits in PAOD.

关键词：前列地尔/投药和剂量前列地尔/药理学前列地尔/治疗应用动脉闭塞性疾病/血液动脉闭塞性疾病/诊断动脉闭塞性疾病/药物疗法运动试验/统计学和数值数据纤维蛋白溶解/药物作用输注静脉内胞间黏附分子1/血液胞间黏附分子1/药物作用疼痛测定外周血管疾病/血液外周血管疾病/诊断外周血管疾病/药物疗法治疗结果血管细胞黏附分子1/血液血管细胞黏附分子1/药物作用老年人女(雌)性人类男(雄)性中年人

来源：评论

学校读者我要写书评

暂无评论

CONVENTIONAL USES OF HEPARIN

引用

THROMBOSIS ET DIATHESIS HAEMORRHAGICA 1975年第1期33卷 97-101页

作者： MCNICOL, GP UNIV LEEDS GEN INFIRMDEPT MEDLEEDS LS1 3EXENGLAND

This paper reviews briefly the use of heparin given by intravenous injection or infusion in amounts designed to prolong the whole blood clotting time in the treatment of established thromboembolic disease.

关键词：抗凝药/治疗应用动脉闭塞性疾病/药物疗法冠心病/药物疗法药物评价肝素/治疗应用肺栓塞/药物疗法蛇毒液类/治疗应用链激酶/治疗应用血栓性静脉炎/药物疗法尿纤溶酶原激活物/治疗应用动物人类

来源：评论

学校读者我要写书评

暂无评论

Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease

引用

AMERICAN HEART JOURNAL 2003年第2期145卷 330-333页

作者： Matsui, K Ikeda, U Murakami, Y Yoshioka, T Shimada, K Jichi Med Sch Div Cardiovasc Med Minami Kawachi Tochigi 3290498 Japan

Objectives Blood monocytes are the precursors of the lipid-laden foam cells that are the hallmark of early atherosclerotic lesions, and monocyte chemoattractant protein-1 (MCP-1) plays important roles in their recruitment to the vessel wall. In this study, we measured serum levels of MCP-1 in patients with peripheral arterial obstructive disease (PAOD) and investigated whether intravenous prostaglandin E 1 (PGE1) treatment, which produces clinical benefits in PAOD, might decrease such levels. Methods Eight patients with PAOD at Fontaine stage 11 to IV were treated with a daily intravenous infusion of 10 mug of PGE1 for 7 consecutive days. Blood samples before and after 7-day PGE1 treatment were used for assays of MCP-1, interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), von Willebrand factor (vWF), and endothelin-1 (ET-1). Results Serum MCP-1 levels in patients with PAOD were significantly higher than those in healthy control subjects (263.8 +/- 52.8 vs 136.5 +/- 15.0 pg/mL, P = .002). PGE1 administration for 7 days resulted in a significant decrease in the MCP-1 level, from 263.8 +/- 52.8 to 196.1 +/- 25.5 pg/mL (P = .02), whereas levels of IL-6, hs-CRP, and ET-1 and the activity of vWF were not affected. Conclusions Serum MCP-1 levels were elevated in patients with PAOD, indicating the involvement of activation of monocytes in the pathogenesis of this disorder. Parenteral administration of PGE1 appeared to decrease circulating MCP-1 levels, which might lead to the suppression of the development of atherosclerotic lesions in patients with PAOD.

关键词：前列地尔/投药和剂量前列地尔/治疗应用动脉闭塞性疾病/血液动脉闭塞性疾病/药物疗法生物学标记/血液 C反应蛋白质/分析病例对照研究趋化因子CCL2/血液内皮缩血管肽1/血液纤维蛋白溶解药/投药和剂量纤维蛋白溶解药/治疗应用注射静脉内白细胞介素6/血液间歇性跛行/血液间歇性跛行/药物疗法外周血管疾病/血液外周血管疾病/药物疗法血管舒张药/投药和剂量血管舒张药/治疗应用 vonWillebrand因子/分析成年人老年人女(雌)性人类男(雄)性中年人

来源：评论

学校读者我要写书评

暂无评论

Complications of thrombolytic therapy for peripheral arterial occlusions

引用

ACTA CHIRURGICA BELGICA 2001年第3期101卷 116-122页

作者： Campbell, WB Royal Devon & Exeter Hosp Exeter EX2 5DW Devon England

Click to increase image sizeClick to decrease image size

关键词：动脉闭塞性疾病/药物疗法纤维蛋白溶解药/治疗应用缺血/药物疗法缺血/病因学腿/血液供给血栓溶解疗法/方法人类

来源：评论

学校读者我要写书评

暂无评论

IMPROVEMENT OF FLOW PROPERTIES OF BLOOD - NEW THERAPEUTIC APPROACH IN OCCLUSIVE ARTERIAL-DISEASE

引用

ANGIOLOGY 1976年第3期27卷 188-196页

作者： EHRLY, AM UNIV FRANKFURT DEPT INTERN MEDDIV ANGIOLD-6000 FRANKFURTFED REP GER

The general pathophysiological basis in occlusive arterial disease is the reduced flow rate of blood in the microcirculation. Blood flow in the ischemic tissue can be increased by improving the flow properties of blood. The fibrinogen concentration of blood and the deformability of red cells are two main factors determining the flow properties of blood. Ancrod, a fibrinogen lowering substance, improves the flow properties of blood by decreasing the viscosity of blood and plasma and by desaggregation of erythrocyte aggregates. Treatment of patients suffering from severe occlusive arterial diseases with Ancrod exhibits surprisingly good results. Disappearance of rest pains and reduction in the use of analgetic drugs has been proved statistically. In the exercising muscles a local hyperosmolarity exists, which is able to decrease the deformability of red cells thereby impairing the flow in narrow capillaries. The addition of Pentoxifyllin to blood in vitro reduces the rigidity of red cells in hyperosmolar blood samples by increasing their cellular ATP content. Thus the reduced flow rate of hyperosmolar blood through 8 μ capillaries could be increased twice (p<0.0005) by the addition of Pentoxifyllin. These in vitro results could be the starting point of a new idea for the treatment of patients with intermittent claudication.

关键词：腺苷三磷酸/血液安克洛酶/药理学安克洛酶/治疗应用动脉闭塞性疾病/血液动脉闭塞性疾病/药物疗法血沉血液黏度/药物作用红细胞聚集/药物作用红细胞变形性/药物作用红细胞/代谢纤维蛋白原/分析微循环容积渗克分子浓度己酮可可碱/药理学己酮可可碱/治疗应用可可碱/类似物和衍生物人类

来源：评论

学校读者我要写书评

暂无评论

Profile of recombinant pro-urokinase given by intraarterial versus intravenous routes of administration in a canine thrombosis model

引用

THROMBOSIS AND HAEMOSTASIS 1999年第2期81卷 301-305页

作者： Burke, SE Lubbers, NL Nelson, RA Wegner, CD Cox, BF Abbott Labs Pharmaceut Discovery Abbott Pk IL 60064 USA

Catheter-directed thrombolysis has gained increasing acceptance for the treatment of patients who present with vascular occlusion;however, intravenous injection may be preferable in selected patients. Recombinant prourokinase (r-proUK) is a recently-developed fibrin-selective thrombolytic agent with specificity for clot-bound plasminogen. To compare the effects of r-proUK on clot lysis and restoration of blood flow when injected by either intraarterial or intravenous routes of administration, we utilized a dog model of arterial thrombosis in which a radiolabelled clot is formed in the femoral artery. The r-proUK was given by intravenous infusion to one group of 18 animals in doses ranging from 10,000 IU/kg to 100,000 IU/kg;a second group of 27 dogs was treated with r-proUK administered by the intra-arterial route in a dose range from 300 IU to 10,000 IU. Clot lysis was measured by monitoring the loss of counts from the radiolabelled clot over time;blood flow was also monitored throughout the experimental period. Animals which received intravenous treatment showed dose-related clot lysis ranging from 14% to 70% at 2 h, while those which received intra-arterial infusions showed lysis ranging from 22% to 79% over the same period. For similar degrees of clot lysis attained at the highest dose levels of 100,000 IU/kg and 10,000 IU, blood flow was restored to 77% and 35% of control levels in dogs which received intravenous and intraarterial treatment, respectively. The hemostatic protein fibrinogen was not reduced in any of the treatment groups. The results indicate that 100 rimes more intravenous than intra-arterial r-proUK is required to produce similar clot lysis in this canine model, and that the agent can be administered at this level without induction of a systemic lytic state.

关键词：动脉闭塞性疾病/药物疗法剂量效应关系药物药物评价临床前股动脉纤维蛋白溶解药/投药和剂量纤维蛋白溶解药/治疗应用后肢/血液供给输注动脉内输注静脉内注射静脉内重组融合蛋白质类/投药和剂量重组融合蛋白质类/治疗应用重组蛋白质类/投药和剂量重组蛋白质类/遗传学重组蛋白质类/治疗应用局部血流/药物作用血栓溶解疗法血栓形成/药物疗法动物狗男(雄)性

来源：评论

学校读者我要写书评

暂无评论

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案：

请选择收藏分类：

通借通还

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：